8-K: Neumora posts FY2025 loss, flags 2026 data catalysts

Neumora reported Q4 and full-year 2025 results, highlighted new NMRA-511 Alzheimer’s agitation data, full enrollment of KOASTAL-2/-3 with Q2 2026 readouts, selected NMRA-898 for schizophrenia, and pushed NMRA-215 to Q1 2027 amid rat tox retest.

Summary

• Cash and securities totaled $182.5 million at December 31, 2025; runway expected into Q3 2027.
• Q4 2025 R&D expense was $44.7 million (vs. $45.9 million in Q4 2024); FY2025 R&D was $176.1 million (vs. $200.9 million in FY2024).
• Q4 2025 G&A expense was $13.8 million (vs. $17.0 million in Q4 2024); FY2025 G&A was $60.1 million (vs. $62.5 million in FY2024).
• Q4 2025 net loss was $59.4 million; FY2025 net loss was $236.9 million (improved from $243.8 million in FY2024).
• NMRA-511 Phase 1b pre-specified analysis (NPI-AA ≥4; n=53) showed Cohen’s d effect sizes of 0.34 on CMAI total and 0.51 on CMAI aggression at Week 8, with favorable tolerability.
• KOASTAL-2 and -3 (navacaprant) fully enrolled in Q1 2026 (each >400 patients); joint topline readout expected in Q2 2026, including pre-specified analyses with >450 patients after 2025 optimizations.
• NMRA-898 designated lead M4 PAM for schizophrenia; Phase 1 data to date show ~80–100-hour half-life, dose-proportional exposures with low variability, PD heart-rate increases consistent with target engagement, and favorable tolerability.
• NMRA-215 obesity program: 12-week DIO mouse data support potential in mechanism-of-action switch and weight maintenance; NOAEL identified in multiple tox studies; unexpected adverse findings in a 13-week rat study triggered a for-cause audit and repeat study; clinical start now targeted for Q1 2027.
• Upcoming milestones: navacaprant KOASTAL-2/-3 topline in Q2 2026; NMRA-511 MAD expansion data in 2H 2026; NMRA-898 MAD data in 2H 2026; Phase 2 NMRA-511 start in Q1 2027; NMRA-215 clinical start in Q1 2027.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as moderately positive given multiple 2026 catalysts and supportive NMRA-511/M4 updates, tempered by continued losses, a thinner cash balance, higher liabilities, and the NMRA-215 tox-driven delay.

Positives

• Strong cash runway into Q3 2027 with $182.5 million in cash, cash equivalents and marketable securities as of December 31, 2025.
• R&D and G&A expenses declined year over year (FY2025 R&D $176.1M vs. $200.9M; FY2025 G&A $60.1M vs. $62.5M), helping narrow the annual net loss.
• NMRA-511 Phase 1b pre-specified analysis showed meaningful effects (Cohen’s d 0.34 on CMAI total; 0.51 on CMAI aggression) with favorable safety, supporting a potential best-in-class profile in AD agitation.
• Navacaprant KOASTAL-2 and -3 fully enrolled (>400 patients each) with joint topline readout expected in Q2 2026, creating a near-term catalyst.
• NMRA-898 (M4 PAM) exhibits ~80–100-hour half-life suggesting once-daily dosing, dose proportionality with low variability, pharmacodynamic evidence of target engagement, and good tolerability to date.
• NMRA-215 obesity program produced positive 12-week DIO mouse results supporting mechanism-of-action switch and maintenance use cases; NOAELs established in multiple species with high margins to predicted human exposures.

Negatives

• Cash balance declined year over year to $182.5 million (from $307.6 million at December 31, 2024).
• Total liabilities increased to $87.2 million (from $29.9 million at December 31, 2024).
• Interest income fell markedly year over year (FY2025 $8.3M vs. $19.9M in FY2024), and interest expense appeared in 2025 ($2.0M).
• Continuing significant net losses (Q4 2025: $59.4M; FY2025: $236.9M) with no product revenue.
• Unexpected adverse findings in a 13-week rat tox study for NMRA-215 necessitated a for-cause audit and study repeat.

Risks

• Comparisons of NMRA-511 outcomes to other sponsors’ pivotal studies may not be directly comparable due to differences in compounds, study designs, and patient characteristics.
• Inherent uncertainty and length of clinical development and regulatory approval processes could delay or prevent product approvals.
• Risks related to timely initiation and enrollment of clinical trials, including reliance on third parties such as CROs.
• Potential for serious or undesirable side effects with therapeutic candidates that could impact development.
• Intellectual property protection risks that could affect competitive position.
• Sufficiency of capital resources to fund operations could be affected by various factors.
• For NMRA-215, unexpected adverse findings in a 13-week rat toxicology study prompted a for-cause audit and a repeat study, which may impact timelines.

Future Outlook

Management expects multiple catalysts in 2026–2027, including KOASTAL-2/-3 topline results in Q2 2026, NMRA-511 higher-dose MAD data in 2H 2026, NMRA-898 MAD data in 2H 2026, initiation of NMRA-511 Phase 2 in Q1 2027, and initiation of NMRA-215 clinical studies in Q1 2027; cash resources are expected to fund operations into Q3 2027.

Management Comments

• CEO Paul L. Berns highlighted significant 2025 progress and positioned 2026 as catalyst-rich, citing confirmation of next steps for navacaprant and the M4 franchise and additional NMRA-511 data supporting an unsurpassed profile in AD agitation.
• Management emphasized strengthened confidence in NMRA-511 following pre-specified analysis effect sizes and favorable tolerability, and designated NMRA-898 as the M4 lead based on Phase 1 attributes.

Industry Context

StockSavvy.ai notes that AD agitation has seen recent momentum with Rexulti’s approval and ongoing development for other agents; Neumora’s NMRA-511 effect sizes in a pre-specified subgroup aim to benchmark against these precedents. In schizophrenia, muscarinic-targeting therapies are an active area (e.g., KarXT/Cobenfy and M4 PAMs like emraclidine), and NMRA-898’s long half-life and PD signal align with class characteristics supportive of once-daily dosing. In obesity, NMRA-215 targets switch/maintenance opportunities amid GLP-1–centered regimens, though translational and tox-related hurdles remain key gating risks.

Comparison to Industry Standards

• AD agitation: Positioning NMRA-511 against benchmarks set by Rexulti and investigational agents like Auvelity relies on effect size comparisons within similar inclusion criteria; Neumora cautions that cross-trial comparisons have limitations, but the reported Cohen’s d values (0.34 total CMAI; 0.51 aggression) are directionally consistent with clinically relevant effects observed in the space.
• Schizophrenia (M4 space): NMRA-898’s ~80–100-hour half-life supports once-daily dosing, comparable to long-acting profiles targeted by M4 PAM peers (e.g., emraclidine) and class pharmacodynamic signals such as heart-rate increases seen with KarXT’s muscarinic activation.
• Capital runway: Funding into Q3 2027 is relatively solid versus many early clinical-stage peers that often guide to 12–24 months, reducing near-term financing risk pending 2026–2027 catalysts.
• Operational discipline: Year-over-year decreases in R&D and G&A mirror cost optimization trends among clinical-stage biotechs, aligning spend with near-term readouts and program prioritization.

Stakeholder Impact

• Shareholders: Multiple near-term clinical catalysts in 2026 could materially affect valuation; cash runway into Q3 2027 reduces immediate financing risk.
• Patients: Potential advancement of novel therapies in AD agitation, schizophrenia, and obesity could expand future treatment options.
• Employees: Program prioritization (e.g., NMRA-898 selection) and clear timelines may focus resources on higher-probability assets.
• Suppliers/CROs: Reliance on CROs and the need to repeat the NMRA-215 rat tox study with a different CRO may shift vendor demand and oversight intensity.
• Creditors: Extended cash runway improves near-term credit profile despite rising liabilities.

Next Steps

• Deliver joint topline results for navacaprant KOASTAL-2 and KOASTAL-3 in Q2 2026.
• Report NMRA-511 MAD expansion cohort data (higher doses) in 2H 2026.
• Report NMRA-898 MAD data in healthy volunteers and stable schizophrenia patients in 2H 2026.
• Complete for-cause audit and repeat the 13-week rat tox study for NMRA-215.
• Initiate NMRA-511 Phase 2 in AD agitation in Q1 2027.
• Initiate NMRA-215 clinical studies in obesity in Q1 2027.

Key Dates

Recommendation

Pipeline momentum and imminent KOASTAL-2/-3 readouts offer upside optionality, while persistent losses, a reduced cash balance with higher liabilities, and a tox-driven delay in NMRA-215 introduce execution risk; maintaining a hold stance is prudent pending Q2 2026 efficacy data.

Keywords

Neumora Therapeutics, NMRA-511, navacaprant, KOASTAL-2, KOASTAL-3, Alzheimer's disease agitation, NMRA-898, M4 PAM, schizophrenia, NMRA-215, obesity, Phase 1b, Phase 2, cash runway, R&D expenses, net loss, clinical timelines